Vaxcyte SVP Elvia Cowan sells $1.6 million in company stock
Vaxcyte's SVP Elvia Cowan sold 19,000 shares for $1.65M, exercised options for 19,000 shares at $25.92 each, and now holds 27,860 shares. Vaxcyte's VAX-31 trial met its primary endpoint, leading to raised price targets from BofA ($130), Guggenheim ($125), and BTIG ($89). The stock is up 63% over the past year but is currently trading at $71.38.
How this was made
The 30-second read
Why it matters
The insider sale adds a short‑term bearish element to an otherwise upbeat news flow.
Market read
The article combines fresh insider‑sale information with recent positive trial news, offering a mixed signal for traders.
What to watch
Recent positive trial data and analyst upgrades may offset the sell‑off pressure.
Background
Vaxcyte reported positive Phase 3 trial results for its VAX‑31 vaccine and raised price targets, while also announcing new executive hires.
Ticker impact
SVP Elvia Cowan sold 19,000 Vaxcyte shares for $1.6 million on Oct 5, 2026 under a Rule 10b5‑1 plan.
likely pressure as investors price in the insider sell
A senior executive offloading a sizable stake often triggers short‑term selling pressure, especially after a recent price rally.
Market effects
Minimal; the sale is company‑specific and does not affect the broader biotech sector.
None; the news is confined to Vaxcyte investors.
Low; no broader market impact.
Counterpoint
The sale could be routine under a pre‑established 10b5‑1 plan and not reflect negative sentiment.
Key entities
- CompanyVaxcyte, Inc.
Biotech firm developing the VAX‑31 vaccine.
- ExecutiveElvia Cowan
Senior Vice President of Finance and Chief Accounting Officer at Vaxcyte.
